Anyone affected by internal bleeding or the loss of a loved one from Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.
Dallas, TX (PRWEB) October 05, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting patients who took the popular blood thinner Pradaxa that the drug has been linked to severe internal bleeding by the Journal for The American Medical Association on September 5, 2012. Also, federal Judge David Herndon issued an order on July 24th denying attempts by Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits.
Anyone affected by internal bleeding or the loss of a loved one after using Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.
Pradaxa is a popular blood thinner prescribed to prevent strokes and blood clots in patients with atrial fibrillation. According to a Wall Street Journal report on April 24, 2012, manufacturer Boehringer Ingelheim has earned over $1 billion from sales of the drug so far in more than 70 countries.
On December 7, 2011, however, the FDA warned that it would launch an investigation into Pradaxa after receiving more injury or death reports than expected. The USA Today reported on August 19, 2012 that the agency received 3,781 reports of side effects and 542 deaths among Pradaxa users last year, leading all other medications in 2011.
On September 5, 2012, The Journal for The American Medical Association also warned that the FDA may have rushed approval of Pradaxa, overlooking key dangers like early trials showing Pradaxa had no reversal agent for internal bleeding. (http://jamanetwork.com)
Due to the number of Pradaxa lawsuits expected, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. On September 5, 2012, the United States Judicial Panel on Multidistrict Litigation indicated more than 100 Pradaxa claims have now been filed.
On July 24th, Judge David Herndon issued an order entitled “Order Denying Motion to Dismiss” denying attempts by Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits. http://www.ilsd.uscourts.gov/opinions/ilsd_live.3.12.cv.611.2107129.0.pdf#search=%22pradaxa%22
Anyone affected by Pradaxa internal bleeding after use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource center only recommends lawyers who are already handling Pradaxa lawsuits.
To speak with a lawyer, or for more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, visit http://www.Pradaxa-lawsuits.org.